# Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)

> **NCT06987942** · PHASE4 · COMPLETED · sponsor: **Sinovac (Dalian) Vaccine Technology Co., Ltd.** · enrollment: 899 (actual)

## Conditions studied

- Varicella
- Influenza Vaccine

## Interventions

- **BIOLOGICAL:** Varicella vaccine+TIV
- **BIOLOGICAL:** Varicella vaccine
- **BIOLOGICAL:** TIV

## Key facts

- **NCT ID:** NCT06987942
- **Lead sponsor:** Sinovac (Dalian) Vaccine Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-21
- **Primary completion:** 2024-11-15
- **Final completion:** 2024-11-15
- **Target enrollment:** 899 (ACTUAL)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06987942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06987942, "Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06987942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*